These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 36914828)
1. Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participants. Aslanis V; Slack RJ; MacKinnon AC; McClinton C; Tantawi S; Gravelle L; Nilsson UJ; Leffler H; Brooks A; Khindri SK; Marshall RP; Pedersen A; Schambye H; Zetterberg F Cancer Chemother Pharmacol; 2023 Mar; 91(3):267-280. PubMed ID: 36914828 [TBL] [Abstract][Full Text] [Related]
2. Relative bioavailability and food effect of the galectin-3 inhibitor selvigaltin (GB1211) administered as a tablet in healthy participants (GALBA-1). Aslanis V; Abd-Elaziz K; Slack RJ; Brinch A; Gravelle L; Morley W; Phung D; Herman K; Holyer I; Poulsen KK; Dogterom P; Tantawi S; Zetterberg FR; Jacoby B; Schambye H; Lindmark B Cancer Chemother Pharmacol; 2024 Nov; 94(5):707-720. PubMed ID: 39167148 [TBL] [Abstract][Full Text] [Related]
3. A phase 1, randomized study to evaluate safety, tolerability, and pharmacokinetics of GDC-3280, a potential novel anti-fibrotic small molecule, in healthy subjects. Cheung D; Fong A; Ding HT; Cabanski CR; Wang J; Chen Y; Bush J; Harris JM; Pan L Pulm Pharmacol Ther; 2021 Aug; 69():102051. PubMed ID: 34166834 [TBL] [Abstract][Full Text] [Related]
4. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects. Taylor L; Gidal B; Blakey G; Tayo B; Morrison G CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683 [TBL] [Abstract][Full Text] [Related]
5. Effects of Single and Multiple Ascending Doses of BI 1358894 in Healthy Male Volunteers on Safety, Tolerability and Pharmacokinetics: Two Phase I Partially Randomised Studies. Fuertig R; Goettel M; Herich L; Hoefler J; Wiebe ST; Sharma V CNS Drugs; 2023 Dec; 37(12):1081-1097. PubMed ID: 38019355 [TBL] [Abstract][Full Text] [Related]
6. Safety, Tolerability, Pharmacokinetics and Quantitative Electroencephalography Assessment of ACD856, a Novel Positive Allosteric Modulator of Trk-Receptors Following Multiple Doses in Healthy Subjects. Önnestam K; Nilsson B; Rother M; Rein-Hedin E; Bylund J; Anderer P; Kemethofer M; Halldin MM; Sandin J; Segerdahl M J Prev Alzheimers Dis; 2023; 10(4):778-789. PubMed ID: 37874100 [TBL] [Abstract][Full Text] [Related]
7. Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses. Guo B; Wu X; Zhang Y; Shi Y; Yu J; Cao G; Zhang J Clin Drug Investig; 2012 Jul; 32(7):475-86. PubMed ID: 22650326 [TBL] [Abstract][Full Text] [Related]
8. A Five-in-One First-in-Human Study To Assess Safety, Tolerability, and Pharmacokinetics of RO7049389, an Inhibitor of Hepatitis B Virus Capsid Assembly, after Single and Multiple Ascending Doses in Healthy Participants. Feng S; Gane E; Schwabe C; Zhu M; Triyatni M; Zhou J; Bo Q; Jin Y Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32839221 [TBL] [Abstract][Full Text] [Related]
9. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease. Hey JA; Yu JY; Versavel M; Abushakra S; Kocis P; Power A; Kaplan PL; Amedio J; Tolar M Clin Pharmacokinet; 2018 Mar; 57(3):315-333. PubMed ID: 29063518 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies. Desai A; Benner L; Wu R; Gertsik L; Uz T; Marek GJ; Zhu T Clin Pharmacokinet; 2021 Jan; 60(1):79-88. PubMed ID: 32533536 [TBL] [Abstract][Full Text] [Related]
11. Safety, Tolerability, and Pharmacokinetics of the Monoamine Oxidase B Inhibitor, HEC122505, and its Major Metabolite After Single- and Multiple- Ascending Dose, and Food Effect Study in Healthy Chinese Subjects. Jin C; Yi C; Chen K; Liang H Eur J Drug Metab Pharmacokinet; 2024 May; 49(3):331-341. PubMed ID: 38446388 [TBL] [Abstract][Full Text] [Related]
12. Randomized, double-blinded, placebo-controlled phase I study of the pharmacokinetics, pharmacodynamics, and safety of KL130008, a novel oral JAK inhibitor, in healthy subjects. Li N; Du S; Wang Y; Zhu X; Shu S; Men Y; He M; Fang F; Wang Y; Gong Y; Chen J; Gu L; Cheng Y; He Q; Lu H; Niu Y; Xu Y; Feng P Eur J Pharm Sci; 2022 Sep; 176():106257. PubMed ID: 35820629 [TBL] [Abstract][Full Text] [Related]
13. Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial. Yuen MF; Agarwal K; Gane EJ; Schwabe C; Ahn SH; Kim DJ; Lim YS; Cheng W; Sievert W; Visvanathan K; Ruby E; Liaw S; Yan R; Huang Q; Colonno R; Lopatin U Lancet Gastroenterol Hepatol; 2020 Feb; 5(2):152-166. PubMed ID: 31711752 [TBL] [Abstract][Full Text] [Related]
14. Results of two Phase 1, Randomized, Double-blind, Placebo-controlled, Studies (Ascending Single-dose and Multiple-dose Studies) to Determine the Safety, Tolerability, and Pharmacokinetics of Orally Administered LX9211 in Healthy Participants. Bundrant L; Hunt TL; Banks P; Gopinathan S; Boehm KA; Kassler-Taub K; Tyle P; Wilson A; Warner C; Wason S Clin Ther; 2021 Jun; 43(6):1029-1050. PubMed ID: 34108079 [TBL] [Abstract][Full Text] [Related]
15. A phase I, randomized, double-blind, placebo-controlled, ascending single- and multiple-dose study of the pharmacokinetics, safety, and tolerability of oral ceftibuten in healthy adult subjects. Hernández-Mitre MP; Wallis SC; Morgan EE; Dudley MN; Loutit JS; Griffith DC; Roberts JA Antimicrob Agents Chemother; 2024 Jan; 68(1):e0109923. PubMed ID: 38059635 [TBL] [Abstract][Full Text] [Related]
16. Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of Mirogabalin in Healthy Chinese Participants: A Randomized, Double-Blind, Placebo-Controlled Study. Li Y; Toyama K; Nakatsu T; Ishizuka H; Wu H; Cao G; Yu J; Wang Y; Liu X; Guo B; Wu J; Yu P; Hong Z; Zhang J; Wu X Adv Ther; 2023 Apr; 40(4):1628-1643. PubMed ID: 36790683 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and Safety of a 1:1 Mixture of Doxecitine and Doxribtimine: Open-label Phase 1 Single Ascending Dose and Food Effect Studies in Healthy Adults. Mittur A; VanMeter SA; Orujov E; Glidden P Clin Ther; 2024 Jul; 46(7):576-587. PubMed ID: 39025716 [TBL] [Abstract][Full Text] [Related]
18. Safety, pharmacokinetics, and antimalarial activity of the novel triaminopyrimidine ZY-19489: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study, pilot food-effect study, and volunteer infection study. Barber BE; Fernandez M; Patel HB; Barcelo C; Woolley SD; Patel H; Llewellyn S; Abd-Rahman AN; Sharma S; Jain M; Ghoghari A; Di Resta I; Fuchs A; Deni I; Yeo T; Mok S; Fidock DA; Chalon S; Möhrle JJ; Parmar D; McCarthy JS; Kansagra K Lancet Infect Dis; 2022 Jun; 22(6):879-890. PubMed ID: 35247321 [TBL] [Abstract][Full Text] [Related]
19. Safety, pharmacokinetics, and efficacy of rifasutenizol, a novel dual-targeted antibacterial agent in healthy participants and patients in China with Helicobacter pylori infection: four randomised clinical trials. Li X; Liu Y; Wang M; Gao L; Liu J; Zhang H; Wu M; Chen H; Lou J; Wang J; Chen J; Geng G; Ma Z; Ding Y Lancet Infect Dis; 2024 Jun; 24(6):650-664. PubMed ID: 38359854 [TBL] [Abstract][Full Text] [Related]
20. Single and Multiple Ascending-dose Studies of Oral Delafloxacin: Effects of Food, Sex, and Age. Hoover R; Hunt T; Benedict M; Paulson SK; Lawrence L; Cammarata S; Sun E Clin Ther; 2016 Jan; 38(1):39-52. PubMed ID: 26581327 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]